PMC:7354481 / 58906-60915 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T72","span":{"begin":357,"end":361},"obj":"Body_part"},{"id":"T73","span":{"begin":582,"end":595},"obj":"Body_part"},{"id":"T74","span":{"begin":1028,"end":1033},"obj":"Body_part"}],"attributes":[{"id":"A72","pred":"uberon_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A73","pred":"uberon_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"},{"id":"A74","pred":"uberon_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Table 4 BioProject data analysis for differential gene expression between non-treated and SARS-CoV-2-treated NEHB and A549 cells.\nWikiPathways p-Adj\nPhotodynamic therapy-induced NF-kB survival signaling 0\nIL-18 signaling pathway 8.6 × 10−9\nmiRNAs involvement in the immune response in sepsis 2.4 × 10−8\nCytokines and Inflammatory Response 9.9 × 10−7\nLung fibrosis 2.5 × 10−6\nBioPlanet p-Adj\nOncostatin M 0\nInterleukin-1 regulation of extracellular matrix 0\nInterleukin-5 regulation of apoptosis 0\nTNF-alpha effects on cytokine activity, cell motility, and apoptosis 0\nImmune system signaling by interferons, interleukins, prolactin, and growth hormones 0\nKEGG p-Adj\nIL-17 signaling pathway 1.3 × 10−9\nTNF signaling pathway 1.6 × 10−9\nLegionellosis 3.5 × 10−9\nRheumatoid arthritis 5.4 × 10−9\nCytokine-cytokine receptor interaction 6.6 × 10−9\nPANTHER p-Adj\nPlasminogen activating cascade 0.00156\nToll receptor signaling pathway 0.00911\nCCKR signaling map ST 0.02550\nApoptosis signaling pathway 0.10282\nBlood coagulation 0.10433\nREACTOME p-Adj\nInterferon alpha/beta signaling 1.6 × 10−9\nInterleukin-10 signaling 2.5 × 10−9\nInterleukin-4 and Interleukin-13 signaling 2.4 × 10−7\nFormation of the cornified envelope 1.3 × 10−5\nChemokine receptors bind chemokines 0.00047\nSmall Molecule Pathway DB p-Adj\nCD40L Signalling Pathway 0.25268\nNF-kB Signaling Pathway 0.25268\nToll-Like Receptor Pathway 2 0.25268\nCapecitabine Metabolism Pathway 0.25268\nCapecitabine Action Pathway 0.25268\nBIOCYC p-Adj\nvitamin D3 biosynthesis 0.03597\nguanosine nucleotides degradation 0.03597\nretinoate biosynthesis II 0.03597\nguanosine nucleotides degradation III 0.03597\nadenosine nucleotides degradation II 0.03597\nPathway Interaction DB p-Adj\nValidated transcriptional targets of AP1 family members Fra1 and Fra2 3.8 × 10−5\nIL23-mediated signaling events 0.00050\nCD40/CD40L signaling 0.02539\nGlucocorticoid receptor regulatory network 0.02603\nLPA receptor mediated events 0.04171"}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T326","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"T327","span":{"begin":753,"end":766},"obj":"Disease"},{"id":"T328","span":{"begin":779,"end":799},"obj":"Disease"},{"id":"T329","span":{"begin":790,"end":799},"obj":"Disease"}],"attributes":[{"id":"A326","pred":"mondo_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A327","pred":"mondo_id","subj":"T327","obj":"http://purl.obolibrary.org/obo/MONDO_0005823"},{"id":"A328","pred":"mondo_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A329","pred":"mondo_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/MONDO_0005578"}],"text":"Table 4 BioProject data analysis for differential gene expression between non-treated and SARS-CoV-2-treated NEHB and A549 cells.\nWikiPathways p-Adj\nPhotodynamic therapy-induced NF-kB survival signaling 0\nIL-18 signaling pathway 8.6 × 10−9\nmiRNAs involvement in the immune response in sepsis 2.4 × 10−8\nCytokines and Inflammatory Response 9.9 × 10−7\nLung fibrosis 2.5 × 10−6\nBioPlanet p-Adj\nOncostatin M 0\nInterleukin-1 regulation of extracellular matrix 0\nInterleukin-5 regulation of apoptosis 0\nTNF-alpha effects on cytokine activity, cell motility, and apoptosis 0\nImmune system signaling by interferons, interleukins, prolactin, and growth hormones 0\nKEGG p-Adj\nIL-17 signaling pathway 1.3 × 10−9\nTNF signaling pathway 1.6 × 10−9\nLegionellosis 3.5 × 10−9\nRheumatoid arthritis 5.4 × 10−9\nCytokine-cytokine receptor interaction 6.6 × 10−9\nPANTHER p-Adj\nPlasminogen activating cascade 0.00156\nToll receptor signaling pathway 0.00911\nCCKR signaling map ST 0.02550\nApoptosis signaling pathway 0.10282\nBlood coagulation 0.10433\nREACTOME p-Adj\nInterferon alpha/beta signaling 1.6 × 10−9\nInterleukin-10 signaling 2.5 × 10−9\nInterleukin-4 and Interleukin-13 signaling 2.4 × 10−7\nFormation of the cornified envelope 1.3 × 10−5\nChemokine receptors bind chemokines 0.00047\nSmall Molecule Pathway DB p-Adj\nCD40L Signalling Pathway 0.25268\nNF-kB Signaling Pathway 0.25268\nToll-Like Receptor Pathway 2 0.25268\nCapecitabine Metabolism Pathway 0.25268\nCapecitabine Action Pathway 0.25268\nBIOCYC p-Adj\nvitamin D3 biosynthesis 0.03597\nguanosine nucleotides degradation 0.03597\nretinoate biosynthesis II 0.03597\nguanosine nucleotides degradation III 0.03597\nadenosine nucleotides degradation II 0.03597\nPathway Interaction DB p-Adj\nValidated transcriptional targets of AP1 family members Fra1 and Fra2 3.8 × 10−5\nIL23-mediated signaling events 0.00050\nCD40/CD40L signaling 0.02539\nGlucocorticoid receptor regulatory network 0.02603\nLPA receptor mediated events 0.04171"}

LitCovid-PD-CLO

LitCovid-PD-CHEBI

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T98","span":{"begin":290,"end":296},"obj":"Phenotype"},{"id":"T99","span":{"begin":779,"end":799},"obj":"Phenotype"}],"attributes":[{"id":"A98","pred":"hp_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/HP_0100806"},{"id":"A99","pred":"hp_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/HP_0001370"}],"text":"Table 4 BioProject data analysis for differential gene expression between non-treated and SARS-CoV-2-treated NEHB and A549 cells.\nWikiPathways p-Adj\nPhotodynamic therapy-induced NF-kB survival signaling 0\nIL-18 signaling pathway 8.6 × 10−9\nmiRNAs involvement in the immune response in sepsis 2.4 × 10−8\nCytokines and Inflammatory Response 9.9 × 10−7\nLung fibrosis 2.5 × 10−6\nBioPlanet p-Adj\nOncostatin M 0\nInterleukin-1 regulation of extracellular matrix 0\nInterleukin-5 regulation of apoptosis 0\nTNF-alpha effects on cytokine activity, cell motility, and apoptosis 0\nImmune system signaling by interferons, interleukins, prolactin, and growth hormones 0\nKEGG p-Adj\nIL-17 signaling pathway 1.3 × 10−9\nTNF signaling pathway 1.6 × 10−9\nLegionellosis 3.5 × 10−9\nRheumatoid arthritis 5.4 × 10−9\nCytokine-cytokine receptor interaction 6.6 × 10−9\nPANTHER p-Adj\nPlasminogen activating cascade 0.00156\nToll receptor signaling pathway 0.00911\nCCKR signaling map ST 0.02550\nApoptosis signaling pathway 0.10282\nBlood coagulation 0.10433\nREACTOME p-Adj\nInterferon alpha/beta signaling 1.6 × 10−9\nInterleukin-10 signaling 2.5 × 10−9\nInterleukin-4 and Interleukin-13 signaling 2.4 × 10−7\nFormation of the cornified envelope 1.3 × 10−5\nChemokine receptors bind chemokines 0.00047\nSmall Molecule Pathway DB p-Adj\nCD40L Signalling Pathway 0.25268\nNF-kB Signaling Pathway 0.25268\nToll-Like Receptor Pathway 2 0.25268\nCapecitabine Metabolism Pathway 0.25268\nCapecitabine Action Pathway 0.25268\nBIOCYC p-Adj\nvitamin D3 biosynthesis 0.03597\nguanosine nucleotides degradation 0.03597\nretinoate biosynthesis II 0.03597\nguanosine nucleotides degradation III 0.03597\nadenosine nucleotides degradation II 0.03597\nPathway Interaction DB p-Adj\nValidated transcriptional targets of AP1 family members Fra1 and Fra2 3.8 × 10−5\nIL23-mediated signaling events 0.00050\nCD40/CD40L signaling 0.02539\nGlucocorticoid receptor regulatory network 0.02603\nLPA receptor mediated events 0.04171"}

LitCovid-PD-GO-BP

LitCovid-sentences

LitCovid-PubTator

PMC:7354481 / 58906-60915 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7354481 / 58906-60915 JSON TXT